Axsome Therapeutics, Inc. (AXSM) is approaching a critical milestone, with the FDA set to deliver its verdict tomorrow, April 30, 2026, on the supplemental New Drug Application (sNDA) for AXS-05 in Alzheimer's disease agitation.
AXS-05 is a fixed-dose combination of dextromethorphan and bupropion. Dextromethorphan is widely known as the active ingredient in cough medicines, while bupropion is prescribed for depression and smoking cessation.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.